Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$28.1K Buy
2,253
+81
+4% +$1.33K ﹤0.01% 1212
2024
Q4
$43K Buy
2,172
+901
+71% +$9.98K ﹤0.01% 882
2024
Q3
$10.4K Sell
1,271
-255
-17% -$1.73K ﹤0.01% 1659
2024
Q2
$10.4K Buy
+1,526
New +$10.4K ﹤0.01% 1604
2023
Q4
Sell
-390
Closed -$959 2768
2023
Q3
$959 Sell
390
-439
-53% -$2.1K ﹤0.01% 2370
2023
Q2
$6.48K Sell
829
-401
-33% -$2.87K ﹤0.01% 1686
2023
Q1
$8.09K Buy
1,230
+554
+82% +$3.67K ﹤0.01% 1588
2022
Q4
$3.93K Buy
676
+314
+87% +$1.96K ﹤0.01% 1943
2022
Q3
$2K Buy
362
+205
+131% +$1.24K ﹤0.01% 2093
2022
Q2
$1K Sell
157
-724
-82% -$4.98K ﹤0.01% 2296
2022
Q1
$7K Sell
881
-162
-16% -$1.38K ﹤0.01% 1455
2021
Q4
$10K Buy
1,043
+85
+9% +$988 ﹤0.01% 1278
2021
Q3
$12K Buy
958
+238
+33% +$3.3K ﹤0.01% 922
2021
Q2
$11K Hold
720
﹤0.01% 1015
2021
Q1
$12K Hold
720
﹤0.01% 943
2020
Q4
$12K Hold
720
﹤0.01% 843
2020
Q3
$27K Sell
720
-46
-6% -$1.44K 0.01% 524
2020
Q2
$17K Buy
766
+114
+17% +$2.44K 0.01% 669
2020
Q1
$6K Buy
+652
New +$9.99K ﹤0.01% 928

Other funds holding MESO

Lindbrook Capital's MESO Position: Q1 2025 in Review

Lindbrook Capital increased its Mesoblast (MESO) stake by 3.7% in Q1 2025, buying an estimated $1.33K and bringing the position to 2,253 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1212.

Lindbrook Capital first reported a position in MESO in Q1 2020 and has held it in 19 quarters since. The position peaked at $43K in Q4 2024. 68 funds tracked by Wall St. Rank hold MESO as of Q1 2025.

  • Lindbrook Capital held 2,253 shares of Mesoblast worth $28.1K as of Q1 2025.
  • Lindbrook Capital bought 81 Mesoblast shares in Q1 2025, an estimated $1.33K.
  • Mesoblast made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1212 holding.
  • Lindbrook Capital first reported a position in Mesoblast in Q1 2020 and has held it in 19 quarters since.
  • Lindbrook Capital's Mesoblast position peaked at $43K in Q4 2024.
  • 68 funds tracked by Wall St. Rank held Mesoblast as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.